Phase III trial of high- vs. low-dose-rate interstitial radiotherapy for early mobile tongue cancer.
OBJECTIVE
Early mobile tongue cancer can be controlled with interstitial radiotherapy (ISRT). We carried out a Phase III trial to compare the treatment results of low-dose-rate (LDR) ISRT and high-dose-rate (HDR) ISRT for early mobile tongue cancer.


METHODS
From April 1992 through October 1996, 59 patients with cancer of the early mobile tongue were registered in this Phase III study. Eight patients were excluded from the evaluation because of violations of the requirements for this study. Of 51 eligible patients, 26 patients were treated with LDR-ISRT (70 Gy/4-9 days) and 25 patients with HDR-ISRT (60 Gy/10 fractions/1 week). For the hyperfractionated HDR-ISRT, the time interval between 2 fractions was more than 6 h.


RESULTS
Five-year local control rates of the LDR and HDR groups were 84% and 87% respectively. Nodal metastasis occurred in 6 patients in each group. Five-year nodal control rates of the LDR and HDR groups were 77% and 76%, respectively.


CONCLUSIONS
Hyperfractionated HDR-ISRT for early mobile tongue cancer has the same local control compared with continuous LDR-ISRT. Hyperfractionated HDR-ISRT is an alternative treatment for continuous LDR-ISRT.
Inoue
T
T
Division of Multidisciplinary Radiotherapy, Biomedical Research Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Inoue
T
T
Yoshida
K
K
Yoshioka
Y
Y
Shimamoto
S
S
Tanaka
E
E
Yamazaki
H
H
Shimizutani
K
K
Teshima
T
T
Furukawa
S
S
D000328:Adult; D000368:Aged; D001918:Brachytherapy / Q000379:methods*; D005260:Female; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality; D011832:Radiation Injuries / Q000209:etiology; D011879:Radiotherapy Dosage; D013997:Time Factors; D014060:Tongue Diseases / Q000209:etiology; D014062:Tongue Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D014456:Ulcer / Q000209:etiology
D007496:Iridium Radioisotopes